- Initial data from the ongoing Phase 1b study evaluating R289, a dual IRAK1/4 inhibitor, in LR-MDS- Additional data for REZLIDHIA® (olutasidenib) in patients with mIDH1 AML and MDS Rigel's ...
SOUTH SAN FRANCISCO, Calif., May 22, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced ...
SOUTH SAN FRANCISCO, June 13, 2019 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will present data on fostamatinib disodium hexahydrate (fostamatinib) in two ...
Final data from the GAVRETO ® (pralsetinib) Phase 1/2 ARROW study in RET fusion-positive NSCLC and other solid tumors ...
-- Growing body of data on REZLIDHIA ® (olutasidenib) in mIDH1 relapsed or refractory (R/R) acute myeloid leukemia (AML) patients -- -- New data on olutasidenib in patients with mIDH1 myelodysplastic ...
Title: Efficacy and Safety of Olutasidenib Monotherapy in Primary Refractory AML: A Post Hoc Analysis of a Phase 2 Study Presenter: Antonio Curti, M.D., Ph.D. In the pivotal cohort of R/R AML patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback